Test Code DRVI3 Dilute Russell's Viper Venom Time (DRVVT) Confirmation Ratio, Plasma
Reporting Name
DRVVT Confirmation RatioPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Confirming the presence or helping to exclude the presence of lupus anticoagulants (LA)
Identifying LA that do not prolong the activated partial thromboplastin time (APTT)
Evaluating unexplained prolongation of the APTT or prothrombin time clotting tests
Distinguishing LA from a specific coagulation factor inhibitor or coagulation factor deficiencies
Method Name
Only orderable as part of a reflex. For more information see DRVI1 / Dilute Russell's Viper Venom Time (DRVVT), with Reflex, Plasma.
Optical Clot-Based
Ordering Guidance
Because no single coagulation test can identify or exclude all lupus anticoagulants (LA), and because of the complexity of testing LA, one of the following Coagulation Consultation reflexive panel procedures are recommended if clinically indicated:
ALUPP / Lupus Anticoagulant Profile, Plasma
AATHR / Thrombophilia Profile, Plasma and Whole Blood
APROL / Prolonged Clot Time Profile, Plasma
Additional Testing Requirements
Serum anticardiolipin antibody testing (CLPMG / Phospholipid [Cardiolipin] Antibodies, IgG and IgM, Serum) and anti-beta-2 glycoprotein I (B2GMG / Beta-2 Glycoprotein 1 Antibodies, IgG and IgM, Serum) antibody testing should also be performed in conjunction with coagulation-based testing for lupus anticoagulants to enhance detection of different types of antiphospholipid antibodies.
Specimen Required
Only orderable as part of a reflex. For more information see DRVI1 / Dilute Russell's Viper Venom Time (DRVVT), with Reflex, Plasma.
Specimen Type: Platelet-poor plasma
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
2. Centrifuge, remove plasma, and centrifuge plasma again.
3. Aliquot into a separate plastic vial, leaving 0.25 mL in the bottom of the centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Specimen Type
Plasma Na CitSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Only orderable as part of a reflex. For more information see DRVI1 / Dilute Russell's Viper Venom Time (DRVVT), with Reflex, Plasma.
<1.20
Normal ranges for children: not clearly established, but similar to normal ranges for adults, except for newborn infants whose results may not reach adult values until 3 to 6 months.
Interpretation
Dilute Russell's viper venom time screen ratio (<1.20):
A normal dilute Russell's viper venom time (DRVVT) screen ratio (<1.20) indicates that lupus anticoagulant (LA) is not present or not detectable by this method (but might be detected with other methods).
An abnormal DRVVT screen ratio (DRVVT screen ratio ≥1.20) may suggest presence of LA, however, other possibilities include:
-Deficiencies or dysfunction of factors I (fibrinogen), II, V, or X, congenital or acquired
-Inhibitors of factor V, or occasionally by inhibitors of factor VIII, or other specific or nonspecific inhibitors
-Anticoagulation therapy effects (see Cautions)
Further evaluation consists of performing mixing studies with an equal volume of normal pooled plasma (DRVVT 1:1 mix) to investigate the possibility of coagulation factor deficiency (suggested by DRVVT mix ratio <1.20) and to evaluate inhibition (suggested by DRVVT mix ratio ≥1.20) and mixing patient plasma with DRVVT reagent enriched in phospholipid (DRVVT confirmatory reagent) (DRVVT mix and DRVVT confirmation ratios).
Possible combinations of results include the following:
-DRVVT screen ratio ≥1.20, DRVVT mix ratio <1.20, and DRVVT confirmation ratio <1.20:
No evidence of LA. These data may reflect anticoagulation therapy effects or other (congenital or acquired) coagulopathy.
-DRVVT screen ratio ≥1.20, DRVVT mix ratio ≥1.20, and DRVVT confirmation ratio <1.20:
The prolonged and inhibited DRVVT (DRVVT screen and mix ratios) may reflect presence of a specific factor inhibitor (eg, factor V inhibitor), anticoagulation therapy effects or other nonspecific inhibitors as can be seen with monoclonal protein disorders, lymphoproliferative disease etc. Although LA cannot be conclusively excluded, the DRVVT confirmation ratio of ≤1.20 makes this less likely.
-DRVVT screen ratio ≥1.20, DRVVT mix ratio <1.20, and DRVVT confirmation ratio ≥1.20:
Although mixing study of the prolonged DRVVT screen and mix ratios provides no evidence of inhibition, additional phospholipid shortens the clotting time (DRVVT confirmation ratio), suggesting presence of LA.
-DRVVT screen ratio ≥1.20, DRVVT mix ratio ≥1.20, and DRVVT confirmation ratio ≥1.20:
The data are consistent with presence of LA, provided anticoagulant effect can be excluded (see Cautions)
DRVVT assays ordered as a single, stand-alone test should be interpreted within patient clinical context and close attention to medication use by patient (see Cautions).
Day(s) Performed
Monday through Friday
Report Available
2 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
85613
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DRVI3 | DRVVT Confirmation Ratio | 50410-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
RCRI3 | DRVVT Confirmation Ratio | 50410-0 |